Cell Renewal – Advanced
The Cell Renewal – Advanced expands the Start protocol to six complementary compounds: the telomerase peptide Epithalon, the senolytic FOXO4-DRI, the mitochondrial-derived peptide Humanin, cellular coenzyme NAD+, the mitochondrial-targeted SS-31 and master-antioxidant Glutathione.
Built for deeper research into senescence clearance, mitochondrial protection and telomere biology – a complete bundled set at a single discounted price.
Original price was: 678,00 €.509,00 €Current price is: 509,00 €.
The expanded 6-part longevity protocol: Epithalon, FOXO4-DRI, Humanin, NAD+, SS-31 and Glutathione.
What's included in this stack
Cell Renewal - Advanced - Expanded Six-Compound Longevity Investigation
Description
Mechanism of Action
The Cell Renewal – Advanced bundle is designed for comprehensive investigation into cellular aging. Epithalon is studied for telomerase activation and telomere maintenance, while the senolytic FOXO4-DRI is researched for selective clearance of senescent cells. Humanin and SS-31 are investigated for mitochondrial protection and cardiolipin stabilization, NAD+ for sirtuin signaling and energy metabolism, and Glutathione for redox balance, together offering a synergistic platform for advanced longevity research.
Benefits
- Targeted Senescent Clearance – FOXO4-DRI is researched for its selective disruption of senescent cell survival pathways, potentially reducing the burden of dysfunctional cells.
- Enhanced Mitochondrial Bioenergetics – NAD+, Humanin, and SS-31 are investigated for their roles in optimizing mitochondrial function, ATP production, and overall cellular energy efficiency.
- Genomic Stability Support – Epithalon is studied for its influence on telomerase activity and telomere maintenance, which are critical for preserving genomic integrity.
- Master Antioxidant Defense – Glutathione is researched as a master antioxidant and for its role in regenerating other antioxidants, supporting cellular protection against oxidative stress.
- DNA Repair & Longevity – NAD+ is investigated as a vital cofactor for sirtuin activation and PARP enzymes, which are crucial for DNA repair and cellular longevity pathways.
- Neuroprotection & Cognition – Humanin and Glutathione are studied for their potential to protect neuronal cells from various stressors and support cognitive function.
- Metabolic & Circadian Balance – NAD+ and Humanin are researched for their influence on glucose homeostasis, insulin sensitivity, and the alignment of cellular processes with circadian rhythms.
- Reduced Inflammatory Signaling – Humanin, NAD+, and FOXO4-DRI are investigated for their roles in attenuating pro-inflammatory cytokine release and reducing the senescence-associated secretory phenotype (SASP).
Research Data
Epithalon
| Study / Model | Reported effect |
|---|---|
| Human somatic cell culture | ↑ Telomerase activity, ↑ telomere length in dividing cells |
| Aged mice longevity studies | Extended median lifespan, ↓ age-related tumor incidence |
| Pineal gland animal models | Restored melatonin secretion rhythm, normalized circadian markers |
| Elderly human observational cohort | Improved sleep architecture, ↑ nocturnal melatonin levels |
| Retinal degeneration rat model | ↓ Photoreceptor loss, preserved retinal pigment epithelium |
| Oxidative stress in vitro assays | ↓ Lipid peroxidation, ↑ antioxidant enzyme expression |
| Immunosenescence rodent studies | Restored T-cell function, normalized thymic activity |
FOXO4-DRI (Proxofim)
| Study / Model | Reported effect |
|---|---|
| Naturally aged mice | ↑ fur density, ↑ renal function markers, improved physical activity |
| Doxorubicin-induced senescence model | Selective clearance of senescent cells, reduced tissue damage |
| Xpd TTD/TTD progeroid mice | Restored fitness, ↓ senescence-associated markers in multiple tissues |
| In vitro senescent fibroblasts (IMR90) | Targeted apoptosis via FOXO4–p53 disruption; healthy cells unaffected |
| Aged mouse kidney tissue | ↓ p21 expression, ↓ SASP factors, improved glomerular function |
| Liver tissue in aged models | Reduced senescent cell burden, ↑ hepatic regeneration markers |
Humanin
| Study / Model | Reported effect |
|---|---|
| Alzheimer’s disease cellular models | ↓ neuronal apoptosis induced by amyloid-beta toxicity; preserved cell viability |
| Aged mouse models | ↑ insulin sensitivity; improved glucose homeostasis and metabolic markers |
| Ischemia-reperfusion (cardiac models) | ↓ infarct size; cardioprotection via STAT3 signaling activation |
| In vitro mitochondrial assays | ↑ mitochondrial respiration and ATP production; reduced oxidative stress |
| Human centenarian observational data | Higher circulating humanin levels correlated with longevity and metabolic health |
| Optic nerve injury models | Retinal ganglion cell survival enhanced; neuroprotective signaling preserved |
| Atherosclerosis rodent models | ↓ plaque formation; reduced vascular inflammation markers |
NAD+
| Study/model | Reported effect |
| Human clinical trials (IV NAD+ administration) | ↑ plasma NAD+ by 4-6×; improved fatigue and alertness scores |
| Animal models (aged mice) | Restored mitochondrial function and ↑ lifespan by 15-20% |
| Cellular aging models | Activation of SIRT1 and PARP1 → enhanced DNA repair and mitochondrial biogenesis |
| Human observational studies | Correlation between low NAD+ and metabolic dysfunction, insulin resistance |
| In vitro neuronal cultures | Protection from oxidative and excitotoxic stress; improved neurite outgrowth |
| Metabolic disorder models | ↓ triglycerides and hepatic steatosis via AMPK activation |
| Exercise recovery studies | ↑ muscle NAD+/NADH ratio and improved endurance performance |
| Brain ischemia models | ↓ infarct size and enhanced neuronal survival post-injury |
SS-31
| Study / Model | Reported effect |
|---|---|
| Aged mouse skeletal muscle | ↑ ATP production, ↓ oxidative damage, improved mitochondrial coupling efficiency |
| Ischemia-reperfusion cardiac model | ↓ infarct size, preserved mitochondrial cristae structure and membrane potential |
| Primary mitochondrial myopathy (clinical) | Improved 6-minute walk distance and reduced patient-reported fatigue |
| Diabetic nephropathy rodent model | ↓ renal oxidative stress, preserved glomerular function and tubular integrity |
| Heart failure (HFrEF) early trials | Trends toward improved left ventricular function and exercise tolerance |
| In vitro cardiolipin-binding assays | Selective localization to inner mitochondrial membrane, stabilized ETC complexes |
| Age-related macular degeneration trials | Improved low-luminance visual acuity and retinal function markers |
Glutathione
| Study/model | Reported effect |
| Human trials (oral and IV administration) | ↑ Plasma GSH levels, ↓ oxidative biomarkers (MDA, 8-OHdG) |
| Animal oxidative stress models | ↓ Lipid peroxidation and improved mitochondrial GSH:GSSG ratio |
| Hepatotoxicity models (CCl4, acetaminophen) | ↓ ALT/AST, ↓ hepatic necrosis, improved antioxidant enzyme activity |
| Neurodegenerative disease models | Protection of dopaminergic neurons and ↓ oxidative stress markers |
| In vitro melanocyte cultures | ↓ Tyrosinase activity and melanin synthesis via GSH-mediated inhibition |
| Inflammatory models | ↓ TNF-α, IL-6, and CRP, supporting immunomodulatory roles |
| Pharmacokinetic assessments | ↑ Cellular uptake with liposomal and SubQ formulations |
Stack Suggestions
This bundle is suited for researchers investigating cellular senescence, mitochondrial decline and telomere biology in advanced research models, providing a robust framework across senolytic, mitochondrial-protective and antioxidant pathways.
Pen Dosage Chart
Epithalon
| Epithalon Pen 20 mg | |
|---|---|
| Volume | 2 mL |
| mg/mL | 10 mg/mL |
| Click-to-Dose | 1 click = 0.1 mg |
| Example(s) | 10 clicks = 1 mg |
FOXO4-DRI (Proxofim)
| FOXO4-DRI (Proxofim) Pen 10 mg | |
|---|---|
| Volume | 2 mL |
| mg/mL | 5 mg/mL |
| Click-to-Dose | 1 click = 0.05 mg |
| Example(s) | 10 clicks = 0.5 mg |
Humanin
| Humanin Pen 10 mg | |
| Volume | 2 mL |
| mg/mL | 5 mg/mL |
| Click-to-Dose | 1 click = 0.05 mg |
| Example(s) | 10 clicks = 0.5 mg |
NAD+
| NAD+ Pen 500 mg | |
| Volume | 3.0 mL |
| mg/mL | 166.67 mg/mL |
| Click-to-Dose | 1 click = 1.67 mg |
| Example(s) | 30 clicks = 50 mg |
| NAD+ Pen 1000 mg | |
| Volume | 3.0 mL |
| mg/mL | 333.33 mg/mL |
| Click-to-Dose | 1 click = 3.33 mg |
| Example(s) | 15 clicks = 50 mg |
SS-31
| SS-31 Pen 10 mg | |
|---|---|
| Volume | 2 mL |
| mg/mL | 5 mg/mL |
| Click-to-Dose | 1 click = 0.05 mg |
| Example(s) | 10 clicks = 0.5 mg |
Glutathione
| Glutathione Pen 1500 mg | |
|---|---|
| Volume | 3 mL |
| mg/mL | 500 mg/mL |
| Click-to-Dose | 1 click = 5 mg |
| Example(s) | 10 clicks = 50 mg |
Dosage & Protocols Variations
Epithalon
Standard Research Protocol
- Dose: 5 – 10 mg (= 50–100 clicks)
- Duration: 2 – 3 weeks
- Frequency: Daily
- Cycle Interval: 4 – 6 months off before repeating
- Goal / Description: Baseline protocol used in telomerase activation and cellular aging models.
Therapeutic Research Protocol
- Dose: 10 – 20 mg (= 100–200 clicks)
- Duration: 10 – 20 days
- Frequency: Daily or split into two administrations
- Cycle Interval: 3 – 6 months off before repeating
- Goal / Description: Higher-dose schedule explored in longevity and pineal signaling research.
Biohacker Protocol (experimental)
- Dose: 2 – 5 mg (= 20–50 clicks)
- Duration: 4 – 6 weeks
- Frequency: 5 days per week
- Cycle Interval: 2 – 3 months off before repeating
- Goal / Description: Microdose continuous approach in experimental aging models.
FOXO4-DRI (Proxofim)
Standard Research Protocol
- Dose: 1.0 – 5.0 mg (= 20–100 clicks)
- Duration: 3 consecutive days
- Frequency: Once every 2 weeks (intermittent pulse)
- Cycle Interval: 2 – 4 weeks off before repeating
- Goal / Description: Baseline senolytic pulsing observed in preclinical aging models.
Therapeutic Research Protocol
- Dose: 5.0 – 10.0 mg (= 100–200 clicks)
- Duration: 3 consecutive days per cycle
- Frequency: 1 cycle every 3 – 4 weeks
- Cycle Interval: 3 – 4 weeks off before repeating
- Goal / Description: Higher-dose pulse evaluated for accelerated senescent cell clearance in research models.
Biohacker Protocol (experimental)
- Dose: 0.5 – 1.0 mg (= 10–20 clicks)
- Duration: 3 consecutive days
- Frequency: Once every 4 – 6 weeks
- Cycle Interval: 4 – 6 weeks off before repeating
- Goal / Description: Microdose pulsing investigated for cumulative senolytic effects with minimal exposure.
Humanin
Standard Research Protocol
- Dose: 1 – 5 mg
- Duration: 4 – 8 weeks
- Frequency: Daily or every other day
- Cycle Interval: 4 weeks off before repeating
- Goal / Description: Baseline protocol for mitochondrial and metabolic research models.
Therapeutic Research Protocol
- Dose: 5 – 10 mg
- Duration: 6 – 12 weeks
- Frequency: Daily
- Cycle Interval: 4 – 6 weeks off before repeating
- Goal / Description: Higher-dose protocol for neuroprotection and insulin sensitivity studies.
Biohacker Protocol (experimental)
- Dose: 0.5 – 1 mg
- Duration: Continuous
- Frequency: Daily microdose
- Cycle Interval: 2 weeks off every 8 weeks
- Goal / Description: Low-dose continuous use in longevity and cellular stress models.
NAD+
Standard Cellular Support
- Dose: 50 – 100 mg (variant 500 mg pen = 30–60 clicks / variant 1000 mg pen = 15–30 clicks)
- Duration: 8 – 12 weeks
- Frequency: Every Other Day
- Cycle Interval: 4-week rest
- Goal / Description: Common research design for mitochondrial and energy studies
Intensive Regeneration Protocol
- Dose: 100 – 250 mg (variant 500 mg pen = 60–150 clicks / variant 1000 mg pen = 30–75 clicks)
- Duration: 8 – 12 weeks
- Frequency: 1× daily
- Cycle Interval: 8-week rest
- Goal / Description: Applied in models focusing on recovery and DNA repair
Neurocognitive Focus Protocol
- Dose: 50 mg (variant 500 mg pen = 30 clicks / variant 1000 mg pen = 15 clicks)
- Duration: 8 – 12 weeks
- Frequency: 1× daily (morning)
- Cycle Interval: 4-week rest
- Goal / Description: Studied for neuronal resilience and alertness optimization
Longevity & Metabolic Protocol
- Dose: 50 – 150 mg (variant 500 mg pen = 30–90 clicks / variant 1000 mg pen = 15–45 clicks)
- Duration: 8 – 12 weeks
- Frequency: Every Other Day
- Cycle Interval: 8-week rest
- Goal / Description: Designed for long-term metabolic and aging research
SS-31
Standard Research Protocol
- Dose: 1 – 5 mg (= 20–100 clicks)
- Duration: 4 – 8 weeks
- Frequency: Daily (subcutaneous)
- Cycle Interval: 2 – 4 weeks off before repeating
- Goal / Description: Baseline mitochondrial support and cardiolipin stabilization in research models.
Therapeutic Research Protocol
- Dose: 5 – 10 mg (= 100–200 clicks)
- Duration: 6 – 12 weeks
- Frequency: Daily
- Cycle Interval: 4 weeks off before repeating
- Goal / Description: Higher-dose protocol for models focused on cardiac, renal, or neurodegenerative mitochondrial dysfunction.
Biohacker Protocol (experimental)
- Dose: 0.5 – 1 mg (= 10–20 clicks)
- Duration: 8 – 12 weeks
- Frequency: Daily microdose
- Cycle Interval: Continuous with periodic 1 – 2 week pauses
- Goal / Description: Low-dose continuous exposure for longevity and oxidative-stress modulation studies.
Stacked Protocol (SS-31 + MOTS-c)
- Dose: 3 – 5 mg SS-31 + 5 mg MOTS-c (= 60–100 clicks)
- Duration: 4 – 6 weeks
- Frequency: Daily
- Cycle Interval: 4 weeks off before repeating
- Goal / Description: Combined mitochondrial biogenesis and membrane stabilization in metabolic research models.
Glutathione
Standard Antioxidant Protocol
- Dose: 200 – 400 mg (= 40–80 clicks)
- Duration: 4 – 8 weeks
- Frequency: 3× weekly
- Cycle Interval: 4-week rest
- Goal / Description: ↑ Systemic antioxidant capacity, baseline redox support
Intensive Detoxification Protocol
- Dose: 500 – 600 mg (= 100–120 clicks)
- Duration: 4 weeks
- Frequency: 5× weekly
- Cycle Interval: 8-week rest
- Goal / Description: Rapid ↑ GSH levels for detoxification models, tissue saturation
Maintenance Protocol
- Dose: 150 mg (= 30 clicks)
- Duration: 8 – 12 weeks
- Frequency: 3× weekly
- Cycle Interval: 8-week rest
- Goal / Description: Long-term maintenance of improved GSH status
Possible Side Effects
This bundle combines multiple research compounds; the per-compound safety notes below apply. For laboratory research use only – not for human consumption.
Epithalon
Epithalon is generally well-tolerated in preclinical and limited human observational studies.
Reported side effects are rare and typically mild:
- Transient drowsiness or mild fatigue following administration.
- Localized irritation, redness, or tenderness at injection site.
- Occasional mild headache during initial dosing periods.
- Temporary changes in sleep patterns linked to pineal signaling modulation.
No evidence of hormonal, hepatic, or systemic adverse effects has been observed in available research data.
FOXO4-DRI (Proxofim)
FOXO4-DRI has been evaluated almost exclusively in preclinical and animal studies, with limited safety data in higher organisms.
Observed effects in experimental models include:
- Transient fatigue or lethargy following administration in animal models.
- Mild injection-site irritation or localized inflammation.
- Short-term changes in blood cell counts during senolytic clearance phases.
- Potential renal stress markers reported in rodent studies at higher doses.
No evidence of long-term systemic, hormonal, or organ-specific toxicity has been reported in available preclinical data; however, human safety profiles remain undefined.
Humanin
Humanin is generally well-tolerated in preclinical and limited human studies, with no major adverse effects reported at research doses.
Observed effects in experimental models are rare and typically mild:
- Transient injection site irritation or redness.
- Mild headache or dizziness during initial dosing.
- Occasional fatigue or drowsiness in early administration phases.
- Minor gastrointestinal discomfort in sensitive subjects.
No evidence of hormonal, hepatic, or cardiovascular adverse effects has been observed in available data. Long-term safety profiles in humans remain under investigation, and Humanin is restricted to experimental and laboratory research.
NAD+
NAD+, as a research coenzyme boosting metabolism, may induce mild side effects in experimental models, primarily during initial administration. These are dose-dependent and often transient. It’s crucial to monitor for subcutaneous reactions.
Headache: Commonly observed at higher doses, manifesting as mild pressure, linked to vascular changes. It typically resolves within days.
Nausea: Occasional gastrointestinal upset, especially with rapid escalation. Frequency decreases with slower protocols.
Dizziness: Lightheadedness reported early on, possibly from energy shifts. Resolves as models adapt.
Flushing: Warm sensation or skin redness, attributed to niacin-like effects.
Fatigue: Paradoxical tiredness initially, due to metabolic adjustments.
Most side effects are minor and manageable through dose titration. Prolonged exposure warrants vigilance for rare issues like hypersensitivity, though uncommon in controlled settings.
SS-31
SS-31 (Elamipretide) has been generally well-tolerated in preclinical and early clinical research settings, with no severe adverse effects reported in available data.
Mild and transient effects observed in research include:
- Localized injection-site reactions, including redness, mild swelling, or irritation.
- Transient headache or dizziness during initial dosing periods.
- Mild gastrointestinal discomfort or nausea in sensitive subjects.
- Occasional fatigue or lightheadedness shortly after administration.
No evidence of hepatic, renal, or hormonal adverse effects has been observed in available research data. Long-term safety profiles remain under investigation in ongoing studies focused on mitochondrial-targeted therapeutics.
Glutathione
Glutathione supplementation is generally well-tolerated due to its endogenous nature, but some individuals may experience side effects, particularly with higher doses or sensitive constitutions. The most common adverse reactions are related to gastrointestinal adjustments and administration site responses with subcutaneous injection protocols.
Gastrointestinal Effects: Mild nausea, abdominal cramping, bloating, and flatulence may occur, especially during the initial supplementation period. These symptoms typically resolve as the body adapts to increased glutathione levels. Some users report a metallic or sulfur-like taste, which is attributed to the cysteine component of the molecule.
Injection Site Reactions: With subcutaneous administration, mild redness, swelling, or irritation at the injection site may occur. These reactions are typically transient and resolve within 24-48 hours. Proper injection technique and site rotation can minimize these effects.
Allergic Reactions: Although rare, some individuals may experience allergic responses including skin rashes, hives, or in severe cases, difficulty breathing. Those with known sensitivities to sulfur-containing compounds should exercise particular caution.
Respiratory Considerations: Individuals with asthma or respiratory sensitivities should avoid inhaled forms, as glutathione may trigger bronchospasms or respiratory distress in predisposed individuals.
Headaches and Fatigue: Some users report mild headaches or temporary fatigue during initial supplementation, likely related to detoxification processes and cellular adjustments to enhanced antioxidant capacity.
It is important to note that most side effects are mild, transient, and resolve with continued use or dosage adjustment. However, individuals should discontinue use and consult healthcare providers if adverse reactions persist or worsen.
Product Attributes
Scientific References
Epithalon
- Peptide promotes overcoming of the division limit in human somatic cell In vitro
- Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells In vitro
- Inhibition of development of spontaneous mammary tumors in mice by Epithalon Animal
- Effect of Epithalon on biomarkers of aging, life span and spontaneous tumor incidence in female rats Animal
- Pineal peptide preparation Epithalamin and tetrapeptide Epitalon: results of clinical use in humans Observational
- Peptides and aging: relevance to cancer prevention and longevity research Animal | In vitro
- Epithalon and aging: experimental and clinical perspectives Observational | Animal
- Telomerase activation and senescence pathways in peptide research In vitro
FOXO4-DRI (Proxofim)
- Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging Animal | In vitro
- FOXO4-DRI peptide selectively induces apoptosis in senescent cells Animal | In vitro
- Senolytics: Eliminating Senescent Cells and Alleviating Intervertebral Disc Degeneration Animal | In vitro
- Cellular senescence: Defining a path forward Observational | Animal | In vitro
- The role of senescent cells in ageing Animal | In vitro
- FOXO4 peptide disrupts FOXO4-p53 interaction to target senescent cells Animal | In vitro
- Senolytic therapy alleviates age-associated bone loss in mice Animal | In vitro
- Therapeutic interventions for aging: the case of cellular senescence Observational | Animal | In vitro
Humanin
- Humanin: a harbinger of mitochondrial-derived peptides? Observational | Animal | In vitro
- Humanin peptide suppresses apoptosis by interfering with Bax activation In vitro
- Humanin: a novel central regulator of peripheral insulin action Animal | In vitro
- Humanin protects against Alzheimer’s disease-relevant insults in vitro and in vivo Animal | In vitro
- The mitochondrial-derived peptide humanin protects RPE cells from oxidative stress, senescence, and mitochondrial dysfunction In vitro
- Naturally occurring variation in the mitochondrial-derived peptide MOTS-c and the risk of type 2 diabetes Observational
- Humanin reduces cardiac ischemia-reperfusion injury via STAT3 signaling Animal
- Humanin and other mitochondrial-derived peptides: bioactive molecules with significant role in healthspan and lifespan Observational | Animal | In vitro
NAD+
- NAD+ therapy in age-related degenerative disorders: A benefit/risk … Review
- The efficacy and safety of β-nicotinamide mononucleotide (NMN … Human RCT
- NAD + Supplementation Normalizes Key Alzheimer’s Features and … Animal
- Effect of Nicotinamide Adenine Dinucleotide on Heart Failure … Review
- Nicotinamide riboside Induced Energy Stress and Metabolic … Animal
- Oral nicotinamide riboside raises NAD+ and lowers biomarkers of … Human RCT
- Nicotinamide riboside, a trace nutrient in foods, is a vitamin B3 with … Review
- safety, insulin-sensitivity, and lipid-mobilizing effects – PubMedHuman RCT
- NAD+ Metabolism in Cardiac Health, Aging, and Disease – PubMed Review
- NAD + -boosting molecules suppress mast cell degranulation and … Animal
SS-31
- Szeto-Schiller Peptides: Mitochondrial-Targeted Peptides for the Treatment of Mitochondrial Disease Animal | In vitro
- Cardiolipin and mitochondrial cristae organization In vitro | Animal
- First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics Animal | In vitro
- Elamipretide (SS-31) Improves Mitochondrial Dysfunction, Synaptic and Memory Impairment Animal
- Elamipretide Improves Mitochondrial Function in the Skeletal Muscle of Older Individuals Human RCT
- Mitochondrial-targeted peptide SS-31 attenuates oxidative stress and renal injury Animal | In vitro
- SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney Disease Animal
- Cardiolipin-targeted peptides rejuvenate mitochondrial function in aged cells In vitro | Animal
Glutathione
- Randomized controlled trial of oral glutathione supplementation on body stores of glutathione Human RCT
- Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function Human RCT
- Glutathione synthesis in the mouse liver supports lipid abundance through NRF2 repression Animal
- Glutathione system enhancement for cardiac protection: pharmacological and clinical data from bench-to-bedside Observational
- Randomized clinical trial of how long-term glutathione supplementation improves lipid metabolism in obese patients with nonalcoholic fatty liver disease Human RCT
- ALSUntangled no. 52: glutathione Human RCT
- Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, clinical trial Human observational
- Systemic glutathione as a skin-whitening agent in adults Human RCT
- Clinical evaluation of glutathione concentrations after consumption of S-acetylglutathione: a pilot study Human observational
- Development of a mouse model expressing a bifunctional glutathione-synthesizing enzyme to study glutathione limitation in vivo Animal
Included In The Box
Every product arrives in a premium, custom-designed PEPTIDE.Power box, engineered for convenience, hygiene, and safe storage in your refrigerator. Inside, you will find everything needed for your full research protocol:
- 1× Disposable Pre-Mixed Injection Pen
- Powered by our proprietary PSM Technology™ – precision stabilization & mixing system for consistent potency
- 10× Ultra-thin Needles (33G, 4 mm)
- 10× Alcohol Pads for sterile preparation
- Internal Stabilizing Foam Insert to prevent shaking during transport
- Instruction Panel printed on the inside of the box for quick reference
- Security Seal Sticker ensuring the package has not been opened or tampered with
Storage
Store the product in a refrigerator at 1 – 8°C immediately upon delivery. To maintain optimal stability, keep the pen away from light, and do not expose it to repeated temperature changes.
Once reconstituted (all our pens come pre-mixed), research compounds remain stable for 6 – 8 weeks under proper refrigeration.
Do not freeze after reconstitution. Always keep the box closed so the pen, needles, and alcohol pads stay clean and protected.
For best results, use the product consistently within the recommended time window and always follow your research protocol.
Delivery
We ship with Next-Day EU Delivery via DHL Express or UPS Express.
All orders are prepared fresh on the day of dispatch, placed in EPS Cold-Chain Transport Boxes, and shipped with cooling elements to maintain a stable temperature throughout the journey.
Our logistics process is designed so the package arrives overnight, avoiding customs delays inside the European Union.
Products are shipped from our EU facility, ensuring no import duties, no customs clearance, and always fast and secure delivery.
Payment
Due to the nature of research peptides and the high-risk category assigned by payment processors, credit card companies do not generally support merchants in this field.
For this reason, we accept mainly Bank Transfers.
We also work with a crypto payment provider, and from time to time, card payments may be available depending on processor availability.
Within the European Union, SEPA transfers are fast, low-cost, and usually arrive within minutes to a few hours, making the payment process smooth and simple.
Once the transfer is received, your order is prepared immediately and dispatched the same day, depending on the daily cut-off time.
Please note that we do not dispatch shipments on Fridays or on days before official public holidays. This is done to ensure that parcels can be delivered on the next working day and are not held in transit over weekends or holidays.
This method ensures compliance, security, and continuity of service for all customers across the EU.
Didn't find the answer to your question?
View all frequently asked questions
